Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B-cell antigen CAR-T cells
- Development stage
- Unknown
- Lead developer
- Beijing Gaobo Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
B-cell antigen CAR-T cells are a category of chimeric antigen receptor (CAR) T-cell therapies engineered to target specific antigens found on the surface of B-lineage cells. In clinical practice, particularly in trials sponsored by Beijing Boren Hospital, this term refers to the use of CAR-T cells directed against targets such as CD19, CD20, or CD22. These therapies are primarily investigated for the treatment of relapsed or refractory mature B-cell lymphomas, including cases with complex presentations like central nervous system (CNS) or maxillofacial involvement. The treatment strategy often involves the sequential administration of different antigen-specific CAR-T products to overcome antigen escape and improve durable remission rates.
- Other names
- B-cell target CAR-T cellsB-cell antigen-directed CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on B-cell antigen CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-cell antigen CAR-T cells.